Now showing items 3328-3347 of 4356

    • R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. 

      Verkooijen, HM; Kerkmeijer, LGW; Fuller, CD; Huddart, R; Faivre-Finn, C; Verheij, M; Mook, S; Sahgal, A; Hall, E; Schultz, C (2017-01)
      The pace of innovation in radiation oncology is high and the window of opportunity for evaluation narrow. Financial incentives, industry pressure, and patients' demand for high-tech treatments have led to widespread ...
    • Rabbit endogenous retrovirus-H encodes a functional protease 

      Voisset, C; Myers, RE; Carne, A; Kellam, P; Griffiths, DJ (2003-01)
      Recent studies have revealed that ‘human retrovirus-5’ sequences found in human samples belong to a rabbit endogenous retrovirus family named RERV-H. A part of the gag-pro region of the RERV-H genome was amplified by PCR ...
    • RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. 

      Lionarons, DA; Hancock, DC; Rana, S; East, P; Moore, C; Murillo, MM; Carvalho, J; Spencer-Dene, B; Herbert, E; Stamp, G; Damry, D; Calado, DP; Rosewell, I; Fritsch, R; Neubig, RR; Molina-Arcas, M; Downward, J (2019-07)
      RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after BRAF V600 and NRAS Q61. Here, we study the role of RAC1P29S in melanoma development and reveal that RAC1P29S activates PAK, AKT, and a ...
    • RACK7 recognizes H3.3G34R mutation to suppress expression of MHC class II complex components and their delivery pathway in pediatric glioblastoma. 

      Jiao, F; Li, Z; He, C; Xu, W; Yang, G; Liu, T; Shen, H; Cai, J; Anastas, JN; Mao, Y; Yu, Y; Lan, F; Shi, YG; Jones, C; Xu, Y; Baker, SJ; Shi, Y; Guo, R (2020-07-17)
      Histone H3 point mutations have been identified in incurable pediatric brain cancers, but the mechanisms through which these mutations drive tumorigenesis are incompletely understood. Here, we provide evidence that RACK7 ...
    • RAD51B in Familial Breast Cancer. 

      Pelttari, LM; Khan, S; Vuorela, M; Kiiski, JI; Vilske, S; Nevanlinna, V; Ranta, S; Schleutker, J; Winqvist, R; Kallioniemi, A; Dörk, T; Bogdanova, NV; Figueroa, J; Pharoah, PDP; Schmidt, MK; Dunning, AM; García-Closas, M; Bolla, MK; Dennis, J; Michailidou, K; Wang, Q; Hopper, JL; Southey, MC; Rosenberg, EH; Fasching, PA; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Surowy, H; Guénel, P; Truong, T; Bojesen, SE; Nordestgaard, BG; Benitez, J; González-Neira, A; Neuhausen, SL; Anton-Culver, H; Brenner, H; Arndt, V; Meindl, A; Schmutzler, RK; Brauch, H; Brüning, T; Lindblom, A; Margolin, S; Mannermaa, A; Hartikainen, JM; Chenevix-Trench, G; kConFab/AOCS Investigators; Van Dyck, L; Janssen, H; Chang-Claude, J; Rudolph, A; Radice, P; Peterlongo, P; Hallberg, E; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Schumacher, F; Simard, J; Dumont, M; Kristensen, V; Borresen-Dale, A-L; Zheng, W; Beeghly-Fadiel, A; Grip, M; Andrulis, IL; Glendon, G; Devilee, P; Seynaeve, C; Hooning, MJ; Collée, M; Cox, A; Cross, SS; Shah, M; Luben, RN; Hamann, U; Torres, D; Jakubowska, A; Lubinski, J; Couch, FJ; Yannoukakos, D; Orr, N; Swerdlow, A; Darabi, H; Li, J; Czene, K; Hall, P; Easton, DF; Mattson, J; Blomqvist, C; Aittomäki, K; Nevanlinna, H (2016-01)
      Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study ...
    • Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. 

      Cohen-Hallaleh, RB; Smith, HG; Smith, RC; Stamp, GF; Al-Muderis, O; Thway, K; Miah, A; Khabra, K; Judson, I; Jones, R; Benson, C; Hayes, AJ (2017-01)
      <h4>Background</h4>Radiation induced angiosarcoma (RIAS) of the breast is a rare and aggressive complication of radiotherapy. Due to the rarity of this disease, much of the evidence for its management is based on case ...
    • Radiation response and cure rate of human colon adenocarcinoma spheroids of different size: the significance of hypoxia on tumor control modelling 

      Buffa, FM; West, C; Byrne, K; Moore, JV; Nahum, AE (2001)
      Purpose: To evaluate the adequacy of a Poisson tumor control probability (tcp) model and the impact of hypoxia on tumor cure. Methods and Materials: A human colon adenocarcinoma cell line, WiDr, was grown as multicellular ...
    • Radiation Safety Culture in the UK Medical Sector: A Top to Bottom Strategy. 

      Chapple, C-L; Bradley, A; Murray, M; Orr, P; Reay, J; Riley, P; Rogers, A; Sandhu, N; Thurston, J (2017-04)
      UK professional bodies have established a number of sectorial working parties to provide guidance on the improvement of radiation safety (RS) culture in the workplace. The medical sector provides unique challenges in this ...
    • Radiation-induced hypopituitarism 

      Fernandez, A; Brada, M; Zabuliene, L; Karavitaki, N; Wass, JAH (BIOSCIENTIFICA LTD, 2009-09)
      The hypothalamic-pituitary unit is a particularly radiosensitive region in the central nervous system. As a consequence, hypopituitarism commonly develops after radiation treatments for sellar and parasellar neoplasms, ...
    • A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. 

      Denis-Bacelar, AM; Chittenden, SJ; Murray, I; Divoli, A; Ralph McCready, V; Dearnaley, DP; O'Sullivan, JM; Johnson, B; Flux, GD (2017-04)
      Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function ...
    • Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. 

      Kerns, SL; Fachal, L; Dorling, L; Barnett, GC; Baran, A; Peterson, DR; Hollenberg, M; Hao, K; Narzo, AD; Ahsen, ME; Pandey, G; Bentzen, SM; Janelsins, M; Elliott, RM; Pharoah, PDP; Burnet, NG; Dearnaley, DP; Gulliford, SL; Hall, E; Sydes, MR; Aguado-Barrera, ME; Gómez-Caamaño, A; Carballo, AM; Peleteiro, P; Lobato-Busto, R; Stock, R; Stone, NN; Ostrer, H; Usmani, N; Singhal, S; Tsuji, H; Imai, T; Saito, S; Eeles, R; DeRuyck, K; Parliament, M; Dunning, AM; Vega, A; Rosenstein, BS; West, CML (2020-02)
      <h4>Background</h4>A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve ...
    • Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. 

      Bryce, AH; Alumkal, JJ; Armstrong, A; Higano, CS; Iversen, P; Sternberg, CN; Rathkopf, D; Loriot, Y; de Bono, J; Tombal, B; Abhyankar, S; Lin, P; Krivoshik, A; Phung, D; Beer, TM (2017-06)
      <h4>Background</h4>Advanced prostate cancer is a phenotypically diverse disease that evolves through multiple clinical courses. PSA level is the most widely used parameter for disease monitoring, but it has well-recognized ...
    • Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. 

      Martins, CD; Kramer-Marek, G; Oyen, WJG (2018-02)
      <h4>Introduction</h4>Radioimmunotherapy (RIT) with monoclonal antibodies and their fragments labelled with radionuclides emitting α -particles, β-particles or Auger electrons have been used for many years in the development ...
    • Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management. 

      Newbold, KL; Flux, G; Wadsley, J (2017-05)
      The management of early stage differentiated thyroid cancer (DTC) with low risk of recurrence has been the subject of much interest and investigation in the recent years. Locally advanced DTC and patients with a high risk ...
    • Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. 

      Nowosielski, M; Ellingson, BM; Chinot, OL; Garcia, J; Revil, C; Radbruch, A; Nishikawa, R; Mason, WP; Henriksson, R; Saran, F; Kickingereder, P; Platten, M; Sandmann, T; Abrey, LE; Cloughesy, TF; Bendszus, M; Wick, W (2018-03)
      <h4>Background</h4>In this exploratory analysis of AVAglio, a randomized phase III clinical study that investigated the addition of bevacizumab (Bev) to radiotherapy/temozolomide in newly diagnosed glioblastoma, we aim to ...
    • Radiological and pathological findings of interval cancers in a multi-centre, randomized, controlled trial of mammographic screening in women from age 40–41 years 

      Evans, AJ; Kutt, E; Record, C; Waller, M; Bobrow, L; Moss, S (2007-04-01)
      Aim The aim of this study was to analyse the radiographic findings of the screening mammograms of women with interval cancer who participated in a multi-centre, randomized, controlled trial of mammographic screening in ...
    • Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. 

      Collins, DC; Sundar, R; Constantidinou, A; Dolling, D; Yap, TA; Popat, S; O'Brien, ME; Banerji, U; de Bono, JS; Lopez, JS; Tunariu, N; Minchom, A (2020-12-09)
      <h4>Background</h4>Malignant pleural mesothelioma (MPM) is traditionally characterized by local destructive spread of the pleura and surrounding tissues. Patient outcomes in MPM with distant metastatic dissemination are ...
    • Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial. 

      Rodriguez Gutierrez, D; Jones, C; Varlet, P; Mackay, A; Warren, D; Warmuth-Metz, M; Sánchez Aliaga, E; Calmon, R; Hargrave, DR; Cañete, A; Massimino, M; Azizi, AA; Le Deley, M-C; Saran, F; Rousseau, RF; Zahlmann, G; Garcia, J; Vassal, G; Grill, J; Morgan, PS; Jaspan, T (2020-01-10)
      BACKGROUND:The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma ...
    • Radiological findings of screen-detected cancers in a multi-centre randomized, controlled trial of mammographic screening in women from age 40 to 48 years 

      Evans, AJ; Kutt, E; Record, C; Walter, M; Moss, S (W B SAUNDERS CO LTD, 2006-09)
      AIM: To elucidate the mammographic findings of screen-detected cancers in women screened between 40-48 years, and to establish the frequency and nature of abnormal findings on previous mammograms in women with screen-detected ...